Michael R. Minogue, Chief Executive Officer, President & Chairman of the Board
Dr. W. Gerald Austen, Edward D. Churchill Professor of Surgery, Harvard Medical School and the Massachusetts General Hospital
Louis E. Lataif, Dean of the Boston University School of Management
Dorothy E. Puhy, Executive Vice President, Chief Financial Officer and Assistant Treasurer, Dana Farber Cancer Institute
Martin P. Sutter, Managing Director, Essex Woodlands Health Ventures
Henri A. Termeer,  Chief Executive Officer, Chairman, and President, Genzyme
Paul G. Thomas, Chief Executive Officer and Founder, Roka Bioscience

Mr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining Abiomed in April 2004, Mr. Minogue acquired the Impella company and established a new mission of creating breakthrough heart support technologies to enable safer revascularization, heart muscle recovery and cost-effective patient solutions. The Impella platform is based on the world’s smallest heart pump on catheters and currently generates more than 80 percent of Abiomed revenue. During Mr. Minogue’s tenure, Abiomed has quadrupled revenue, raised over $100 million in capital, tripled market capitalization and become cash positive with no debt. Pertaining to product development, over the last eight years, Abiomed has earned 15 regulatory approvals on new products related to the CE Mark, 510(k), PMA and HDE.  Prior to joining Abiomed, Mr. Minogue completed a successful 11 year career at GE Healthcare. He departed GE as the Vice President of Americas Sales and Marketing for the $1B Information Technology business. At GE, Mr. Minogue held various leadership positions in sales, marketing, service, product engineering and software development.  The experience includes the diagnostics of diseases from cancer to heart failure and in various technologies such as MRI, CT, PET, X-ray, Cardiology, and Patient Information and Monitoring. Prior to Abiomed and GE, Mr. Minogue served as an infantry officer in the U.S. Army for four years and 8 years Individual Ready Reserve, which included multiple distinctions including Airborne RANGER, Combat Infantryman’s badge, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago. Mr. Minogue holds three patents, currently serves on the executive board of directors for AdvaMed, was formerly on the board for LifeCell Corporation (LIFC), which was acquired in May 2008; and provides personal support for organizations helping military veterans and wounded warriors.

Dr. W. Gerald Austen, M.D., has served as a Director of the Company since 1985. Since 1974 he has been the Edward D. Churchill Professor of Surgery at Harvard Medical School and at Massachusetts General Hospital. From 1969 to 1997, Dr. Austen was Chief of the Surgical Services at Massachusetts General Hospital. Dr. Austen is the former President of the American College of Surgeons, the American Association for Thoracic Surgery, the American Surgical Association and the Massachusetts and American Heart Associations. Dr. Austen is a member of the Institute of Medicine of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a life member of the corporation of the Massachusetts Institute of Technology and Chairman of the Board of Trustees of the John S. and James L. Knight Foundation.

Mr. Louis E. Lataif joined ABIOMED’s Board of Directors in September 2005. Mr. Lataif has served as Dean of Boston University School of Management since 1991. Prior to joining Boston University, he worked at Ford Motor Company for more than 27 years and retired as a corporate officer. He had also served as President of Ford of Europe and has extensive global experience. Mr. Lataif earned a BS from Boston University and an MBA from Harvard University. He is the recipient of three honorary doctoral degrees.

Ms. Dorothy E. Puhy has served as a Director of the Company and chair of its Audit Committee since 2003. Ms. Puhy is currently Executive Vice President, Chief Financial Officer and Assistant Treasurer for the Dana-Farber Cancer Institute (“Dana-Farber”). Ms. Puhy has served as the Chief Financial Officer of Dana-Farber since 1994 and has served as its Assistant Treasurer since 1995. From 1985 to 1994 Ms. Puhy held various financial positions at the New England Medical Center Hospitals, Inc., including Chief Financial Officer from 1989 to 1994.

Mr. Martin P. Sutter is one of the two founding managing directors of Essex Woodlands, one of the oldest and one of the largest life sciences/healthcare focused venture capital firms with nearly $3 billion under management.  Mr. Sutter has more than 30 years of management experience in operations, marketing, finance and venture capital.  Mr. Sutter currently serves on the Board of Directors of QSpex Technologies, Inc.  He formerly sat on the Boards of ATS Medical which was acquired by Medtronic, Inc., BioForm Medical which was acquired by Merz GmbH & Co KGaA, LifeCell which was acquired by Kinetic Concepts, Inc., St. Francis Medical Technologies which was acquired by Kyphon, Inc./Medtronic, Inc., Confluent Surgical which was acquired by Tyco International and Rinat Neuroscience which was acquired by Pfizer Inc.  Mr. Sutter is also responsible for the partnership’s investment in NeoVista and Spinal Concepts, which was acquired by Abbott Laboratories.

Mr. Henri A. Termeer has served as a Director of the Company since 1987. Mr. Termeer has been the president and a director of Genzyme Corporation since 1983, its Chief Executive Officer since 1985, and its chairman since 1988. Mr. Termeer is a member of the Harvard Medical School Board of Fellows, Chairman of the Harvard Medical School Genetics Advisory Council, and Chairman of the New England Healthcare Institute (NEHI). He also serves on the board of directors of the Biotechnology Industry Organization (BIO), the Pharmaceutical Research and Manufacturers of American (PhRMA) and is a trustee of Hambrecht & Quist Healthcare Investors and Hambrecht & Quist Life Sciences Investors.

Mr. Paul G. Thomas is Chief Executive Officer and Founder of Roka Bioscience, a company focused on the development and commercialization of molecular assays and is a Director of Orthovita, Inc. (NASDAQ:  VITA).  Mr. Thomas previously served as Chairman, Chief Executive Officer and President of LifeCell Corporation until it was acquired by KCI in 2008 and also held various senior positions during his tenure of 15 years with Ohmeda.  Mr. Thomas received his M.B.A. degree from Columbia University Graduate School of Business, completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science and received his B.S. degree in Chemistry from St. Michael’s College in Vermont.